{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T15:04:21Z","timestamp":1761059061477},"reference-count":15,"publisher":"Wiley","issue":"1","license":[{"start":{"date-parts":[[2006,1,25]],"date-time":"2006-01-25T00:00:00Z","timestamp":1138147200000},"content-version":"vor","delay-in-days":1607,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Annals of the New York Academy of Sciences"],"published-print":{"date-parts":[[2001,9]]},"abstract":"<jats:p><jats:bold>A<jats:sc>bstract<\/jats:sc>: <\/jats:bold> Pentostatin is a highly lymphocytotoxic agent active in hairy cell leukemia. Several studies also suggest significant activity in T cell lymphomas manifested in the skin. Herein, we will review the studies of pentostatin in these lymphomas and our most recent trial of this agent in heavily pretreated patients with cutaneous and peripheral T cell lymphomas. Overall, the data suggest that pentostatin has significant antitumor activity in these patients, with response rates ranging from 33% to over 70%. Approximately one\u2010third of the responses are complete. The most common side effects include granulocytopenia, nausea, and renal insufficiency. CD4 suppression occurs and may result in an increased risk of herpes zoster infection. Although prolonged remissions have been seen, most responses are short\u2010lived. These observations suggest that further exploration of this agent, in combination with other drugs active in T cell lymphomas, is warranted in this group of diseases.<\/jats:p>","DOI":"10.1111\/j.1749-6632.2001.tb03724.x","type":"journal-article","created":{"date-parts":[[2010,7,20]],"date-time":"2010-07-20T23:21:06Z","timestamp":1279668066000},"page":"200-205","source":"Crossref","is-referenced-by-count":13,"title":["Therapy of T Cell Lymphomas with Pentostatin"],"prefix":"10.1111","volume":"941","author":[{"given":"RAZELLE","family":"KURZROCK","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2006,1,25]]},"reference":[{"key":"e_1_2_5_2_2","doi-asserted-by":"publisher","DOI":"10.1002\/jhet.5570110438"},{"key":"e_1_2_5_3_2","doi-asserted-by":"publisher","DOI":"10.1038\/bjc.1991.423"},{"key":"e_1_2_5_4_2","unstructured":"Cummings F.J. A. Tsiatis M. O'Connell et al.1986. Phase II trial of low dose 2\u2010deoxycoformycin in refractory malignant lymphomas [abstract]. Proc. Am. Assoc. Clin. Res. 27: 197."},{"key":"e_1_2_5_5_2","first-page":"835a","article-title":"An investigation of deoxycoformycin in advanced cutaneous T\u2010cell lymphoma (CTCL) [abstract]","volume":"33","author":"Grever M.R.","year":"1985","journal-title":"Proc. Am. Assoc. Clin. Res."},{"key":"e_1_2_5_6_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0190-9622(97)80279-4"},{"key":"e_1_2_5_7_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1994.12.12.2588"},{"key":"e_1_2_5_8_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0190-9622(88)70224-8"},{"key":"e_1_2_5_9_2","first-page":"52","article-title":"Pentostatin (Nipent) in T\u2010cell malignancies","volume":"27","author":"Ho A.D.","year":"2000","journal-title":"Semin. Oncol."},{"key":"e_1_2_5_10_2","doi-asserted-by":"crossref","first-page":"2385","DOI":"10.1182\/blood.V88.7.2385.bloodjournal8872385","article-title":"Mycosis fungoides and S\u00e9zary syndrome","volume":"88","author":"Diamandidou E.","year":"1996","journal-title":"Blood"},{"key":"e_1_2_5_11_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V84.5.1361.1361"},{"key":"e_1_2_5_12_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2400513"},{"key":"e_1_2_5_13_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1999.17.10.3117"},{"key":"e_1_2_5_14_2","doi-asserted-by":"publisher","DOI":"10.2165\/00003495-199346040-00006"},{"key":"e_1_2_5_15_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM198704023161401"},{"key":"e_1_2_5_16_2","doi-asserted-by":"crossref","first-page":"4061","DOI":"10.1182\/blood.V84.12.4061.bloodjournal84124061","article-title":"Long\u2010term follow\u2010up of patients with hairy cell leukemia after treatment with 2\u2032deoxycoformycin","volume":"84","author":"Kraut E.H.","year":"1994","journal-title":"Blood"}],"container-title":["Annals of the New York Academy of Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1749-6632.2001.tb03724.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/nyaspubs.onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1749-6632.2001.tb03724.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,25]],"date-time":"2023-09-25T15:31:25Z","timestamp":1695655885000},"score":1,"resource":{"primary":{"URL":"https:\/\/nyaspubs.onlinelibrary.wiley.com\/doi\/10.1111\/j.1749-6632.2001.tb03724.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2001,9]]},"references-count":15,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2001,9]]}},"alternative-id":["10.1111\/j.1749-6632.2001.tb03724.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1749-6632.2001.tb03724.x","archive":["Portico"],"relation":{},"ISSN":["0077-8923","1749-6632"],"issn-type":[{"value":"0077-8923","type":"print"},{"value":"1749-6632","type":"electronic"}],"subject":[],"published":{"date-parts":[[2001,9]]}}}